Myungmoon Pharm명문제약

Myungmoon Pharm is near break-even on a trailing basis, with a thin operating margin, a net loss over the last twelve months and a share price well below its 52-week high.

Trailing twelve-month revenue is about ₩199.8B with operating income of about ₩1.5B and a net loss of about ₩1.7B as of H1 2026. The company sells cholesterol-lowering and other prescription medicines mainly in Korea, with a golf and real estate services segment, and its shares closed at ₩1,314 on 2026-10-19, down 22% over one year.

What stands out

• Revenue grew in 2025 to about ₩195.2B (+4.7%), with operating income of about ₩6.8B and a net profit of about ₩1.9B, after losses in 2023 and 2024.
• Trailing free cash flow is negative at about -₩3.6B, and borrowings are not reported in the data while liabilities are 192% of equity.
• Cash of about ₩24.1B is reported, and the stock trades at 0.5x book value and 0.2x sales, with no dividend.
• Foreign ownership rose slightly to 1.9% from 1.6% over 60 days, while retail investors were net sellers over the last 20 days.
• Recent filings are mainly insider shareholding reports and the half-year report for June 2026; no news headlines are included in the data.

What to watch

• The next full-year or quarterly results, to see whether 2025's profit recovers or the trailing net loss persists.
• Further insider shareholding reports and any changes in the company's cash flow and debt position.
• Whether the company's cholesterol-drug sales hold up, since the data does not describe pipeline or regulatory risks in detail.